23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Advanced Heart Failure and End-Stage Heart Failure: Does a Difference Exist

      review-article

      Read this article at

      ScienceOpenPublisherPMC
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Advanced heart failure (AdHF) represents a challenging aspect of heart failure patients. Because of worsening clinical symptoms, high rates of re-hospitalization and mortality, AdHF represents an unstable condition where standard treatments are inadequate and additional interventions must be applied. A heart transplant is considered the optimal therapy for AdHF, but the great problem linked to the scarcity of organs and long waiting lists have led to the use of mechanical circulatory support with ventricular-assist device (VAD) as a destination therapy. VAD placement improves the prognosis, functional status, and quality of life of AdHF patients, with high rates of survival at 1 year, similar to transplant. However, the key element is to select the right patient at the right moment. The complete assessment must include a careful clinical evaluation, but also take into account psychosocial factors that are of crucial importance in the out-of-hospital management. It is important to distinguish between AdHF and end-stage HF, for which advanced therapy interventions would be unreasonable due to severe and irreversible organ damage and, instead, palliative care should be preferred to improve quality of life and relief of suffering. The correct selection of patients represents a great issue to solve, both ethically and economically.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          Heart failure: preventing disease and death worldwide

          Heart failure is a life-threatening disease and addressing it should be considered a global health priority. At present, approximately 26 million people worldwide are living with heart failure. The outlook for such patients is poor, with survival rates worse than those for bowel, breast or prostate cancer. Furthermore, heart failure places great stresses on patients, caregivers and healthcare systems. Demands on healthcare services, in particular, are predicted to increase dramatically over the next decade as patient numbers rise owing to ageing populations, detrimental lifestyle changes and improved survival of those who go on to develop heart failure as the final stage of another disease. It is time to ease the strain on healthcare systems through clear policy initiatives that prioritize heart failure prevention and champion equity of care for all. Despite the burdens that heart failure imposes on society, awareness of the disease is poor. As a result, many premature deaths occur. This is in spite of the fact that most types of heart failure are preventable and that a healthy lifestyle can reduce risk. Even after heart failure has developed, premature deaths could be prevented if people were taught to recognize the symptoms and seek immediate medical attention. Public awareness campaigns focusing on these messages have great potential to improve outcomes for patients with heart failure and ultimately to save lives. Compliance with clinical practice guidelines is also associated with improved outcomes for patients with heart failure. However, in many countries, there is considerable variation in how closely physicians follow guideline recommendations. To promote equity of care, improvements should be encouraged through the use of hospital performance measures and incentives appropriate to the locality. To this end, policies should promote the research required to establish an evidence base for performance measures that reflect improved outcomes for patients. Continuing research is essential if we are to address unmet needs in caring for patients with heart failure. New therapies are required for patients with types of heart failure for which current treatments relieve symptoms but do not address the disease. More affordable therapies are desperately needed in the economically developing world. International collaborative research focusing on the causes and treatment of heart failure worldwide has the potential to benefit tens of millions of people. Change at the policy level has the power to drive improvements in prevention and care that will save lives. It is time to make a difference across the globe by confronting the problem of heart failure.
            • Record: found
            • Abstract: found
            • Article: not found

            Eighth annual INTERMACS report: Special focus on framing the impact of adverse events.

            The Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database now includes >20,000 patients from >180 hospitals.
              • Record: found
              • Abstract: not found
              • Article: not found

              The epidemiology of heart failure: The Framingham Study

                Author and article information

                Journal
                Diagnostics (Basel)
                Diagnostics (Basel)
                diagnostics
                Diagnostics
                MDPI
                2075-4418
                01 November 2019
                December 2019
                : 9
                : 4
                : 170
                Affiliations
                [1 ]Department of Cardiovascular, Respiratory, Nephrology, Anesthesiology and Geriatric Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy; paolo.severino@ 123456uniroma1.it (P.S.); puccimariateresa@ 123456gmail.com (M.P.); marcoval.mariani@ 123456gmail.com (M.V.M.); fabio.infu@ 123456gmail.com (F.I.); ilariabirtolo@ 123456gmail.com (L.I.B.); viviana.maestrini@ 123456uniroma1.it (V.M.); massimo.mancone@ 123456uniroma1.it (M.M.)
                [2 ]Department of Medicine, Division of Cardiology University of Pennsylvania, Perelman School of Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA
                Author notes
                [* ]Correspondence: francesco.fedele@ 123456uniroma1.it ; Tel.: +39-064-997-9021; Fax: +39-064-997-9060
                Author information
                https://orcid.org/0000-0001-6211-4482
                https://orcid.org/0000-0001-5483-8472
                https://orcid.org/0000-0002-9480-1209
                https://orcid.org/0000-0002-3225-8378
                Article
                diagnostics-09-00170
                10.3390/diagnostics9040170
                6963179
                31683887
                f57b0522-c757-4b39-9ed7-a51bf96a386a
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 14 September 2019
                : 29 October 2019
                Categories
                Review

                advanced heart failure,end stage heart failure,ventricular assist device,orthotopic heart transplant,hlm classification

                Comments

                Comment on this article

                Related Documents Log